175 related articles for article (PubMed ID: 33243068)
1. Retrospective survival analysis in patients with metastatic pancreatic ductal adenocarcinoma with insulin-treated type 2 diabetes mellitus.
Pretta A; Ziranu P; Puzzoni M; Lai E; Orsi G; Liscia N; Molinaro E; Mariani S; Riggi L; Rovesti G; Dubois M; Migliari M; Persano M; Saba G; Impera V; Musio F; Batzella E; Demurtas L; Pusceddu V; Astara G; Faloppi L; Casadei Gardini A; Andrikou K; Cascinu S; Scartozzi M
Tumori; 2021 Dec; 107(6):550-555. PubMed ID: 33243068
[TBL] [Abstract][Full Text] [Related]
2. Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment.
Pretta A; Ziranu P; Giampieri R; Donisi C; Cimbro E; Spanu D; Lai E; Pecci F; Balconi F; Lupi A; Pozzari M; Persano M; Murgia S; Pusceddu V; Puzzoni M; Berardi R; Scartozzi M
Dig Liver Dis; 2023 May; 55(5):655-660. PubMed ID: 36513569
[TBL] [Abstract][Full Text] [Related]
3. Metformin Improves Survival in Patients with Pancreatic Ductal Adenocarcinoma and Pre-Existing Diabetes: A Propensity Score Analysis.
Amin S; Mhango G; Lin J; Aronson A; Wisnivesky J; Boffetta P; Lucas AL
Am J Gastroenterol; 2016 Sep; 111(9):1350-7. PubMed ID: 27430290
[TBL] [Abstract][Full Text] [Related]
4. Oncological benefit of metformin in patients with pancreatic ductal adenocarcinoma and comorbid diabetes mellitus.
Terasaki F; Sugiura T; Okamura Y; Ito T; Yamamoto Y; Ashida R; Ohgi K; Uesaka K
Langenbecks Arch Surg; 2020 May; 405(3):313-324. PubMed ID: 32367394
[TBL] [Abstract][Full Text] [Related]
5. Medically managed hypercholesterolemia and insulin-dependent diabetes mellitus preoperatively predicts poor survival after surgery for pancreatic cancer.
Chagpar RB; Martin RC; Ahmad SA; Kim HJ; Rupp C; Weber S; Ebelhar A; Gilbert J; Brinkman A; Winslow E; Cho CS; Kooby D; Chu CK; Staley CA; McMasters KM; Scoggins CR
J Gastrointest Surg; 2011 Apr; 15(4):551-7. PubMed ID: 21327533
[TBL] [Abstract][Full Text] [Related]
6. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
[TBL] [Abstract][Full Text] [Related]
7. Reduced mean platelet volume levels predict shorter survival in patients with resectable pancreatic ductal adenocarcinoma and type 2 diabetes.
Yin JB; Li N; Cui MM; Wang X; Wang RT
BMC Gastroenterol; 2020 May; 20(1):143. PubMed ID: 32393273
[TBL] [Abstract][Full Text] [Related]
8. Diabetes associated with pancreatic ductal adenocarcinoma is just diabetes: Results of a prospective observational study in surgical patients.
Dugnani E; Gandolfi A; Balzano G; Scavini M; Pasquale V; Aleotti F; Liberati D; Di Terlizzi G; Petrella G; Reni M; Doglioni C; Bosi E; Falconi M; Piemonti L
Pancreatology; 2016; 16(5):844-52. PubMed ID: 27546476
[TBL] [Abstract][Full Text] [Related]
9. Impact of Nab-Paclitaxel-based Second-line Chemotherapy in Metastatic Pancreatic Cancer.
Dadi N; Stanley M; Shahda S; O'Neil BH; Sehdev A
Anticancer Res; 2017 Oct; 37(10):5533-5539. PubMed ID: 28982867
[TBL] [Abstract][Full Text] [Related]
10. Resolution of new-onset diabetes after radical pancreatic resection predicts long-term survival in patients with pancreatic ductal cell adenocarcinoma.
He XY; Li JF; Yao WY; Yuan YZ
Ann Surg Oncol; 2013 Nov; 20(12):3809-16. PubMed ID: 23943021
[TBL] [Abstract][Full Text] [Related]
11. Prognosis following surgical bypass compared with laparotomy alone in unresectable pancreatic adenocarcinoma.
Insulander J; Sanjeevi S; Haghighi M; Ivanics T; Analatos A; Lundell L; Del Chiaro M; Andrén-Sandberg Å; Ansorge C
Br J Surg; 2016 Aug; 103(9):1200-8. PubMed ID: 27250937
[TBL] [Abstract][Full Text] [Related]
12. Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma.
Reni M; Peretti U; Zanon S; Macchini M; Balzano G; Mazza E; Tamburrino D; Orsi G; Arcidiacono PG; Falconi M; Gianni L
Cancer Chemother Pharmacol; 2020 Apr; 85(4):641-650. PubMed ID: 32157412
[TBL] [Abstract][Full Text] [Related]
13. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP
Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211
[TBL] [Abstract][Full Text] [Related]
14. Incidence of Venous Thromboembolism in Patients With Newly Diagnosed Pancreatic Cancer and Factors Associated With Outcomes.
Frere C; Bournet B; Gourgou S; Fraisse J; Canivet C; Connors JM; Buscail L; Farge D;
Gastroenterology; 2020 Apr; 158(5):1346-1358.e4. PubMed ID: 31843588
[TBL] [Abstract][Full Text] [Related]
15. Adverse Oncologic Impact of New-Onset Diabetes Mellitus on Recurrence in Resected Pancreatic Ductal Adenocarcinoma: A Comparison With Long-standing and Non-Diabetes Mellitus Patients.
Lee S; Hwang HK; Kang CM; Lee WJ
Pancreas; 2018 Aug; 47(7):816-822. PubMed ID: 29975349
[TBL] [Abstract][Full Text] [Related]
16. Antidiabetic therapies affect risk of pancreatic cancer.
Li D; Yeung SC; Hassan MM; Konopleva M; Abbruzzese JL
Gastroenterology; 2009 Aug; 137(2):482-8. PubMed ID: 19375425
[TBL] [Abstract][Full Text] [Related]
17. The Main Bottleneck for Non-Metastatic Pancreatic Adenocarcinoma in Past Decades: A Population-Based Analysis.
Li Y; Liu W; Zhao L; Xu Y; Yan T; Yang Q; Pei Q; Güngör C
Med Sci Monit; 2020 May; 26():e921515. PubMed ID: 32358953
[TBL] [Abstract][Full Text] [Related]
18. Changes in CRP and CA19-9 during Preoperative Oncological Therapy Predict Postoperative Survival in Pancreatic Ductal Adenocarcinoma.
Nurmi AM; Mustonen H; Haglund C; Seppänen H
Oncology; 2021; 99(11):686-698. PubMed ID: 34412062
[TBL] [Abstract][Full Text] [Related]
19. Presence of pancreatic intraepithelial neoplasia-3 in a background of chronic pancreatitis in pancreatic cancer patients.
Hwang IK; Kim H; Lee YS; Kim J; Cho JY; Yoon YS; Han HS; Hwang JH
Cancer Sci; 2015 Oct; 106(10):1408-13. PubMed ID: 26183380
[TBL] [Abstract][Full Text] [Related]
20. Clinical impact of sarcopenia on prognosis in pancreatic ductal adenocarcinoma: A retrospective cohort study.
Ninomiya G; Fujii T; Yamada S; Yabusaki N; Suzuki K; Iwata N; Kanda M; Hayashi M; Tanaka C; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
Int J Surg; 2017 Mar; 39():45-51. PubMed ID: 28110029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
